The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

researchers reported in the journal Diabetes, Obesity and Metabolism. The problem is that these Glucagon-like peptide-1 (GLP-1) drugs were initially approved to treat type 2 diabetes, and later ...

The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a ...

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. They were originally developed to treat type 2 diabetes, which happens ...